ArticleCell reports. Medicine2022
Plasmodium vivax malaria serological exposure markers: Assessing the degree and implications of cross-reactivity with P. knowlesi.
Article in Cell reports. Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Immunodominant B-cell epitopes for precision surveillance ofEmerging microbes & infections · 2026Article
- Predicting Risk of Plasmodium Vivax Microscopy-Detected Episodes Using Serological Markers in Patients With Plasmodium falciparum Malaria: A Multicountry Diagnostic Performance Evaluation.The Journal of infectious diseases · 2026Article
- Assessing the effect of parasite antigen genetic diversity on performance of Plasmodium vivax serological exposure markers for malaria: a multicentre observational diagnostic accuracy study.The Lancet. Microbe · 2026Observational
- PTRAMP, CSS and Ripr form a conserved complex required for merozoite invasion of Plasmodium species into erythrocytes.Nature communications · 2026Article
- A novel micronemal protein MP38 is involved in the invasion of merozoites into erythrocytes.mBio · 2025Article
- Applying novel Plasmodium Vivax serological exposure markers to quantify residual malaria transmission in the Philippines through repeated health facility surveys: the SMaRT study protocol.BMC infectious diseases · 2025Article
- Evaluating the technical feasibility of serological testing and treatment forThe Lancet regional health. Western Pacific · 2025Article
- Genomic exploration of the journey of Plasmodium vivax in Latin America.PLoS pathogens · 2025Article
- Plasmodium vivax serological exposure markers: PvMSP1-42-induced humoral and memory B-cell response generates long-lived antibodies.PLoS pathogens · 2024Article
- Characterization of merozoite-specific thrombospondin-related anonymous protein (MTRAP) inFrontiers in cellular and infection microbiology · 2024Article
- Article
- In Silico Analysis Reveals High Levels of Genetic Diversity ofTropical medicine and infectious disease · 2023Article
- Using Serological Markers for the Surveillance ofPathogens (Basel, Switzerland) · 2023Article
- Naturally acquired antibody response toFrontiers in cellular and infection microbiology · 2023Article
- Optimizing Plasmodium vivax serological surveillance within a coendemic epidemiological landscape.Trends in parasitology · 2022Article
Corrections and comments
- Commented on by
Authors and funding
24 authors at 10 institutions in 6 countries.
Funding
Abstract
Serological markers are a promising tool for surveillance and targeted interventions for Plasmodium vivax malaria. P. vivax is closely related to the zoonotic parasite P. knowlesi, which also infects humans. P. vivax and P. knowlesi are co-endemic across much of South East Asia, making it important to design serological markers that minimize cross-reactivity in this region. To determine the degree of IgG cross-reactivity against a panel of P. vivax serological markers, we assayed samples from human patients with P. knowlesi malaria. IgG antibody reactivity is high against P. vivax proteins with high sequence identity with their P. knowlesi ortholog. IgG reactivity peaks at 7 days post-P. knowlesi infection and is short-lived, with minimal responses 1 year post-infection. We designed a panel of eight P. vivax proteins with low levels of cross-reactivity with P. knowlesi. This panel can accurately classify recent P. vivax infections while reducing misclassification of recent P. knowlesi infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.